Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Toxicology. 2018 May 3;404-405:25–32. doi: 10.1016/j.tox.2018.05.003

Fig. 5.

Fig. 5

Over-expression of PPARβ/δ or PPARγ suppresses ectopic tumors from squamous cell carcinoma cell line A431. Two million cells were subcutaneously injected into the hind quarter leg of athymic NCR-nu/nu male mice (N=5). Mice were orally administered control, GW0742 (5 mg/kg), or rosiglitazone (Rosi; 20 mg/kg) three days per week beginning on Day 3. Data represents the mean ± SEM. (A) Average tumor volumes from A431-MigR1 (MigR1) or A431-hPPARβ/δ (hPPARβ/δ) cells with or without ligand activation of PPARβ/δ with GW0742. (B) Average tumor volumes from A431-MigR1 (MigR1) or A431-hPPARγ (hPPARγ) cells with or without ligand activation of PPARγ with rosiglitazone. #Significantly different than control (p ≤ 0.05).